Alphatec Holdings (NASDAQ: ATEC), a leading medical technology company focused on spinal disorder treatments, saw its stock surge by 21.17% in pre-market trading on October 31, 2024. This surge came on the heels of the company's impressive third-quarter 2024 financial results and raised full-year guidance.

For the quarter ended September 30, 2024, Alphatec reported record revenue of $151 million, surpassing analyst expectations of $147.2 million. The company's surgical revenue grew by a remarkable 30% year-over-year, driving the overall 27% increase in total revenue. Additionally, Alphatec achieved a 19% growth in new surgeon adoption, a key leading indicator of future growth potential.

Buoyed by the strong quarterly performance, Alphatec raised its full-year 2024 revenue guidance to $605 million, representing a 25% increase compared to the previous year. The company also increased its full-year adjusted EBITDA guidance to $27 million, up from the previous expectation of $25.5 million, reflecting its commitment to expanding profitability and improving cash flow.

While Alphatec reported a net loss of $39.6 million for the quarter, its adjusted EBITDA margin improved significantly to 4.9%, up from -0.4% in the same quarter last year, indicating progress towards profitability. The company also announced an expansion of its existing term loan facility by $50 million, increasing its total capacity to $200 million and providing additional financial flexibility.

Analysts generally maintained positive ratings and price targets on Alphatec, citing its strong growth prospects and strategic initiatives, such as driving adoption through surgeon training and its ecosystem of tools and technologies aimed at improving surgical outcomes. However, some analysts cautioned about ongoing risks and financial constraints, including managing spending and resources effectively, converting trained surgeons into active users, and addressing upcoming debt maturities.

Despite these challenges, Alphatec's innovations and focus on enhancing spine care seem to be driving its momentum, as evidenced by the stock's pre-market surge following its robust Q3 performance and raised 2024 outlook.